BAY3389934

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

100 competitors in Sepsis

#DrugCompanyPhaseTrials

1

Antibiotics

MMelinta Therapeutics, Inc.

Phase 3

22

N-Acetylcysteine (NAC) Treatment

TThe First Affiliated Hospital of Soochow University

Phase 3

13

Decadron

AAspen Global Incorporated

Phase 2

14

Nafamostat Mesylate

EEnsysce Biosciences

Phase 3

25

Hydrocortisone Administration

UUniversity of Virginia

Phase 3

16

Simdax

Orion Corporation, Orion Pharma

Preclinical

17

Zyvox

Pfizer

Preclinical

—8

Zemplar

AbbVie

Preclinical

—9

Primaxin

Pfizer

Preclinical

—10

Levophed

GGeneral Hospital of Ningxia Medical University

Preclinical

3Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Sepsis1 trial

First in Patient, Dose Escalation, Open Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion of BAY 3389934 to Patients With Sepsis Induced Coagulopathy

Recruiting·Bayer·Phase 1·NCT06854640·36 enrolled

Unspecified1 trial

Open-label Randomized, Three-fold Cross-over, Single-center Interaction Study to Investigate the Influence of Multiple Doses of Acetylsalicylic Acid (ASA) (Aspirin) on the Pharmacodynamics of BAY 3389934 in Healthy Participants.

Recruiting·Bayer·Phase 1·NCT07652723·16 enrolled

Details

Drug Info

Related News